lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
4,817 rows where filing_period = "second_quarter" and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3375473 | MCDERMOTT+ LLC da2609c5-f548-4b4e-9d09-b299d477d1c1 | Q2 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2025 | second_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in thefederal discount drug purchasing program. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2025-06-30T16:06:11-04:00 | |
| 3375776 | TAUZIN STRATEGIC NETWORKS cdf566d8-c965-4ecd-a053-7fa4564c994b | Q2 | TAUZIN STRATEGIC NETWORKS | 400786367 | RAZORMETRICS | 2025 | second_quarter | PHA | Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 37500 | 0 | 0 | 2025-07-01T13:29:57-04:00 | |
| 3375820 | DA VINCI GROUP e996d85d-f639-4db3-87a9-5dc9193840f1 | Q2 | DA VINCI GROUP | 11548 | BOESEN & SNOW, LLC | 2025 | second_quarter | PHA | Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-07-01T14:46:57-04:00 | |
| 3375867 | E3 STRATEGIC CONSULTING GROUP f0f4bac9-f255-48cb-a50f-0a9666ec0ff5 | Q2 | E3 STRATEGIC CONSULTING GROUP | 401104104 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2025 | second_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-01T16:22:34-04:00 | |
| 3376152 | REPUBLIC CONSULTING, LLC b26f63f8-f15c-444e-93e5-f8392a7b6f8f | Q2 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2025 | second_quarter | PHA | monitor health data policy. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-02T13:51:05-04:00 | |
| 3376307 | DAVE KOLBE CONSULTING f1c9d792-038a-4d57-8f3f-14d37d70fdfa | Q2 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2025 | second_quarter | PHA | H.R. 2880 Protecting Patients Against PBM Abuses Act - Discuss updated jobs study, MFN price control and PBM Reform. | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2025-07-03T10:22:34-04:00 | |
| 3376522 | HEALTHSPERIEN 3d6233d7-b0b3-49a7-bc3e-3447e3156240 | Q2 | HEALTHSPERIEN | 401103150 | EXACT CARE PHARMACY | 2025 | second_quarter | PHA | Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 40500 | 0 | 0 | 2025-07-03T15:58:33-04:00 | |
| 3377041 | AMERICAN COLLEGE OF CLINICAL PHARMACY 913d64ec-b0a8-4867-950e-eb53eca1f3cb | Q2 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2025 | second_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2025-07-07T11:10:51-04:00 | |
| 3377511 | MASON STREET CONSULTING, LLC 89bffa60-99a3-447e-84c9-270524899725 | Q2 | MASON STREET CONSULTING, LLC | 401105150 | CAPITAL RX INC. | 2025 | second_quarter | PHA | PBM Reform. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-08T11:07:11-04:00 | |
| 3377513 | MASON STREET CONSULTING, LLC 7801054c-fef6-46d6-b5a1-45ec173313fd | Q2 | MASON STREET CONSULTING, LLC | 401105150 | DOMPE US INC. | 2025 | second_quarter | PHA | Tariffs on orphan drugs. | Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),White House Office | 30000 | 0 | 0 | 2025-07-08T11:08:27-04:00 | |
| 3377672 | SURESCRIPTS 73b3d41f-b09f-4490-b9a3-558a067ae6a3 | Q2 | SURESCRIPTS | 401109459 | SURESCRIPTS | 2025 | second_quarter | PHA | Efforts to advance health data interoperability; ensure technological advances in the pharmacy services sector, including electronic prescribing ofcontrolled substances, real-time pharmacy benefit information to patients and other stakeholders. Efforts to promote equitable community access to pharmacist services. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-07-08T13:31:32-04:00 | |
| 3377836 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 97287987-807d-4f00-b23f-0e5f76d1780e | Q2 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2025 | second_quarter | PHA | Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing. | HOUSE OF REPRESENTATIVES,White House Office | 50000 | 0 | 0 | 2025-07-08T15:59:22-04:00 | |
| 3377926 | FOLEY & LARDNER LLP 470511d8-96ea-4d9b-9638-28e7dd69839e | Q2 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2025 | second_quarter | PHA | Issues related to Domestic manufacturing; Issues related to 340B; implementation of the Inflation Reduction Act; Issues related to supply chain resilience; Issues related to trade policy. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2025-07-08T19:45:39-04:00 | |
| 3378442 | VENABLE LLP 9ba78515-d80e-49f3-94b9-2f78bd555df9 | Q2 | VENABLE LLP | 39941 | MEDISCA INC. | 2025 | second_quarter | PHA | FDA policy; matters related to pharmacy compounding; trade issues related to compounding | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-09T14:43:15-04:00 | |
| 3378678 | PENN AVENUE PARTNERS 90abb1af-875a-4c23-8609-8874426d4f72 | Q2 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2025 | second_quarter | PHA | Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.1 - One Big Beautiful Bill Act. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 70000 | 0 | 0 | 2025-07-09T21:38:49-04:00 | |
| 3378743 | PENN AVENUE PARTNERS 89fe1423-4108-4044-ae46-590262a5326a | Q2 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2025 | second_quarter | PHA | Pharmacy benefit related issues. H.R.1 - One Big Beautiful Bill Act. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 90000 | 0 | 0 | 2025-07-10T05:58:16-04:00 | |
| 3378941 | POLSINELLI PC 00907d59-5816-4fe5-9a07-b890ed45345c | Q2 | POLSINELLI PC | 314911 | RESQ PHARMA | 2025 | second_quarter | PHA | FDA Regulatory Issues | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2025-07-10T11:58:44-04:00 | |
| 3379404 | ACG ADVOCACY 691b0b87-17fa-4a7c-af94-6f970a28f33a | Q2 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2025 | second_quarter | PHA | Drug pricing policy issues. Data privacy. Provider status legislation. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-10T15:42:23-04:00 | |
| 3379466 | MR. H.R. BERT PENA a0807d76-ac00-4ec7-a944-8b65a91324f0 | Q2 | MR. H.R. BERT PENA | 400323519 | MARGO RX LLC(DBA RICHARD'S PHARMACY) | 2025 | second_quarter | PHA | PBM issues | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 0 | 0 | 2025-07-10T16:07:09-04:00 | ||
| 3381019 | NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION 9f806dee-bd23-4e80-96eb-833eb746e7d9 | Q2 | NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION | 27786 | NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION | 2025 | second_quarter | PHA | 340B | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2025-07-14T10:59:26-04:00 | ||
| 3381875 | AMERICAN VETERINARY MEDICAL ASSOCIATION e70a61ce-976f-4300-aae6-23428fb44d3d | Q2 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2025 | second_quarter | PHA | Xylazine; Combating Illicit Xylazine Act (HR1266/S545); Controlled Substances used in veterinary medicine, Controlled Substances Act and regulations as related to veterinary medicine. Issues related to the FDA CVM. | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2025-07-14T15:47:58-04:00 | |
| 3381993 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d329523d-6d82-4db8-92e2-27a4b6841380 | Q2 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2025 | second_quarter | PHA | Opioid Abuse - General issues related to access to medication assisted treatment General Issues Related to report language regarding paper inserts Implementation of Public Law 113-54 (DSCSA) | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 515760 | 0 | 0 | 2025-07-14T16:27:59-04:00 | |
| 3382485 | WAKEFERN FOOD CORP. fc959f0b-5f8b-42fa-8604-d50178e5c0c6 | Q2 | WAKEFERN FOOD CORP. | 400588798 | WAKEFERN FOOD CORP. | 2025 | second_quarter | PHA | Protecting Pharmacies In Medicaid Act (S. 927) Patients Before Middlemen Act (S. 882) Prescription Drug Transparency and Affordability Act (H.R. 2450) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2025-07-15T09:48:36-04:00 | ||
| 3382591 | WAXMAN STRATEGIES b05f50e3-97af-429a-8555-62a1231998f0 | Q2 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2025 | second_quarter | PHA | Issues affecting the 340B drug pricing program; Appropriations for 340B program. | HOUSE OF REPRESENTATIVES,SENATE | 39000 | 0 | 0 | 2025-07-15T10:39:38-04:00 | |
| 3382661 | THE HARPLE GROUP, LLC cbfac454-1f7c-47f1-9500-fd6d05a5ce0d | Q2 | THE HARPLE GROUP, LLC | 401108916 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA) | 2025 | second_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, and prescription drug pricing Pharmacy Benefit Manager Transparency Act of 2023; Prescription Pricing for the People Act of 2023; HELP Copays Act; Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); Lowering Drug Costs for American Families Act; Protecting Patients Against PBM Abuses Act; The Drug Act; Lower Costs, More Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-15T11:03:41-04:00 | |
| 3382993 | AMERICAN PHARMACISTS ASSOCIATION 8d1a5a14-0334-4bdb-942c-493b85b8d1e6 | Q2 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2025 | second_quarter | PHA | PBM reform Pharmacist payment reform | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2025-07-15T12:52:46-04:00 | |
| 3383069 | THE ROTUNDA GROUP LLC c7303ce4-fafc-4d45-bed6-445d0171b8fe | Q2 | THE ROTUNDA GROUP LLC | 401104124 | HEALTHPLAN DATA SOLUTIONS, INC. | 2025 | second_quarter | PHA | pharmacy benefit reform; pharmacy payment integrity | HOUSE OF REPRESENTATIVES | 10000 | 0 | 0 | 2025-07-15T13:43:10-04:00 | |
| 3383124 | AMERICAN SOCIETY OF CONSULTANT PHARMACISTS 28d967b5-64fb-4250-8cba-80b1c35cf578 | Q2 | AMERICAN SOCIETY OF CONSULTANT PHARMACISTS | 3446 | AMERICAN SOCIETY OF CONSULTANT PHARMACISTS | 2025 | second_quarter | PHA | Reimbursement for pharmacists' services | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2025-07-15T14:15:49-04:00 | |
| 3383706 | KOUNTOUPES DENHAM CARR & REID, LLC b6eee63d-4c0f-434e-a2ce-bd6c80104f93 | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | AMERICAN KRATOM ASSOCIATION | 2025 | second_quarter | PHA | Issues related to Food and Drug Administration regulatory and consumer access. Issues related to the Federal Kratom Consumer Protection Act, and the Fiscal Year 2026 Agriculture Appropriations bills. | HOUSE OF REPRESENTATIVES | 50000 | 0 | 0 | 2025-07-15T17:33:55-04:00 | |
| 3383850 | LMH STRATEGIC SOLUTIONS 512c158b-264c-4477-844a-b414050f9317 | Q2 | LMH STRATEGIC SOLUTIONS | 401108183 | AVADEL PHARMACEUTICALS, PLC | 2025 | second_quarter | PHA | Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. VA Appropriations Request. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-15T20:51:58-04:00 | |
| 3383859 | LMH STRATEGIC SOLUTIONS da744348-7bb3-43bb-87ec-3c881c439f25 | Q2 | LMH STRATEGIC SOLUTIONS | 401108183 | GLAXOSMITHKLINE LLC | 2025 | second_quarter | PHA | Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-15T21:05:09-04:00 | |
| 3383883 | LMH STRATEGIC SOLUTIONS ae4bce7d-6c4f-4104-880f-2cecd8f7543e | Q2 | LMH STRATEGIC SOLUTIONS | 401108183 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | second_quarter | PHA | Pharmaceutical Supply Chain. H.R.2213 - Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832 - EPIC Act of 2025. | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2025-07-15T21:32:15-04:00 | |
| 3384583 | PORT SIDE STRATEGIES, LLC 4f761193-6e0d-4354-b875-add3406870c5 | Q2 | PORT SIDE STRATEGIES, LLC | 401105394 | CENTER FOR HEALTH AND DEMOCRACY | 2025 | second_quarter | PHA | Issues related to pharmacy benefit managers. S. 1753 End Price Gouging for Medications Act - in support. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-16T11:42:53-04:00 | |
| 3384623 | PORT SIDE STRATEGIES, LLC 742e6bc7-26e6-4d46-81a0-ca5336ab9f2a | Q2 | PORT SIDE STRATEGIES, LLC | 401105394 | SOCIAL SECURITY WORKS | 2025 | second_quarter | PHA | H.R.3162 - Affordable and Safe Prescription Drug Importation Act of 2025 - in support. S.1836 - SMART Prices Act - in support. S. 1753 End Price Gouging for Medications Act - in support. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-16T11:49:23-04:00 | |
| 3384690 | SQUIRE PATTON BOGGS cdb78e87-d7cb-472e-bb16-6c29d255a42c | Q2 | SQUIRE PATTON BOGGS | 30906 | SK AMERICAS, INC. | 2025 | second_quarter | PHA | US pharmaceutical policies. | HOUSE OF REPRESENTATIVES,SENATE | 180000 | 0 | 0 | 2025-07-16T12:02:55-04:00 | |
| 3384943 | VERTEX PHARMACEUTICALS INCORPORATED d4013a0c-114b-4834-958d-175ba7710491 | Q2 | VERTEX PHARMACEUTICALS INCORPORATED | 40027242 | VERTEX PHARMACEUTICALS INCORPORATED | 2025 | second_quarter | PHA | Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families. | HOUSE OF REPRESENTATIVES,SENATE | 1140000 | 0 | 0 | 2025-07-16T12:56:33-04:00 | |
| 3384990 | BALLARD PARTNERS 26b5b750-8474-4655-b099-364433ebf492 | Q2 | BALLARD PARTNERS | 401104288 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2025 | second_quarter | PHA | Lower healthcare costs, pharmacy coverage and reimbursement issues, (does not include any PBM issues). | Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 90000 | 0 | 0 | 2025-07-16T13:02:46-04:00 | |
| 3385068 | SALT POINT STRATEGIES 53a6259f-4e96-4b06-8a38-62e978701880 | Q2 | SALT POINT STRATEGIES | 401105514 | VERTEX PHARMACEUTICALS | 2025 | second_quarter | PHA | Non-opioid pain relief and drug pipeline issues. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-16T13:14:32-04:00 | |
| 3385077 | ALB SOLUTIONS 6dbc12f3-f7ac-4870-a95a-ba86f2336f54 | Q2 | ALB SOLUTIONS | 401105973 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2025 | second_quarter | PHA | Issues related to regulatory and legislative developments regarding biosimilars and prescription digital therapeutics. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-16T13:16:12-04:00 | |
| 3385166 | INVARIANT LLC 4317558b-70e1-4e85-9fec-fbcfbb02b197 | Q2 | INVARIANT LLC | 314237 | SK AMERICAS, INC. | 2025 | second_quarter | PHA | Monitor proposals and issues related to biopharmaceuticals. Educate policymakers on SK Pharmteco's active pharmaceutical ingredient manufacturing capabilities. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2025-07-16T13:37:01-04:00 | |
| 3385222 | KOUNTOUPES DENHAM CARR & REID, LLC 804a0c8a-3613-4cc5-9e06-0e2fce0b184a | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2025 | second_quarter | PHA | Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-16T13:52:46-04:00 | |
| 3385352 | CHARTWELL STRATEGY GROUP LLC bcbc9e07-2fb3-4e23-8224-bb7d15f5d53f | Q2 | CHARTWELL STRATEGY GROUP LLC | 401104750 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2025 | second_quarter | PHA | Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing. Monitor FY 2026 Appropriations. Support direct primary care and telehealth provisions in H.R. 1 (reconciliation legislation). Monitor and engage on EU & Canadian digital regulatory policies (including digital services taxes). Monitor international trade issues. Monitor labor issues. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-16T14:14:50-04:00 | |
| 3385665 | KOUNTOUPES DENHAM CARR & REID, LLC 3f3b93e0-5afa-43b4-b4bb-22fbb498d7db | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2025 | second_quarter | PHA | General issues related to over-the-counter (OTC) pharmaceutical supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-16T14:46:38-04:00 | |
| 3385967 | KOUNTOUPES DENHAM CARR & REID, LLC 01d39795-baeb-42b9-bb07-55809bece7b9 | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2025 | second_quarter | PHA | Issues related to pharmaceutical supply chains and patient access. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-16T15:29:41-04:00 | |
| 3385971 | OMEGA STRATEGIES LLC (DC) 70b3f7d9-4b80-416d-8a92-ed2f1c123e73 | Q2 | OMEGA STRATEGIES LLC (DC) | 401108551 | ON DEMAND PHARMACEUTICALS | 2025 | second_quarter | PHA | Advocated on issues related to drug shortages | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-16T15:29:53-04:00 | |
| 3386272 | BROWNSTEIN HYATT FARBER SCHRECK, LLP d57ed91c-39e4-489a-af8e-6917fdf0e651 | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | CENCORA, INC. | 2025 | second_quarter | PHA | Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement. | HOUSE OF REPRESENTATIVES | 60000 | 0 | 0 | 2025-07-16T16:24:41-04:00 | |
| 3386287 | NATIONAL GROCERS ASSOCIATION aa9e9d20-c660-4878-b464-694bfa451cf5 | Q2 | NATIONAL GROCERS ASSOCIATION | 27924 | NATIONAL GROCERS ASSOCIATION | 2025 | second_quarter | PHA | Pharmacy Direct and Indirect Remuneration Fee Reform Pharmacy Benefit Manager Transparency Pharmacy Quality Measures Standardized pharmacy performance measures Any Willing Pharmacy | HOUSE OF REPRESENTATIVES,SENATE | 225240 | 0 | 0 | 2025-07-16T16:28:18-04:00 | |
| 3386312 | MANATOS & MANATOS 4af75ce4-3c4b-462a-912c-c37ac361d18a | Q2 | MANATOS & MANATOS | 23634 | VANDA PHARMACEUTICALS INC | 2025 | second_quarter | PHA | FDA approval of specific medical drugs | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2025-07-16T16:33:17-04:00 | ||
| 3386473 | BALLARD PARTNERS bbf24489-1be0-4477-bc06-8c061dd0d594 | Q2 | BALLARD PARTNERS | 401104288 | NOVO NORDISK INC. | 2025 | second_quarter | PHA | Guidance regarding pharmaceutical regulations. | Health & Human Services, Dept of (HHS) | 40000 | 0 | 0 | 2025-07-16T16:54:43-04:00 | |
| 3386805 | RAY ANDERSON e4bc20a7-0c60-4e9c-b765-94cf2e39a44a | Q2 | RAY ANDERSON | 401105487 | 340B HEALTH | 2025 | second_quarter | PHA | 340B regulatory policy regarding contract harmacy 340B regulatory policy regarding a proposed rebate payment model | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES | 21000 | 0 | 0 | 2025-07-16T19:04:07-04:00 | |
| 3387044 | FORBES-TATE 3d8e3d51-725c-45cd-8689-58823061f531 | Q2 | FORBES-TATE | 400976792 | PHRMA | 2025 | second_quarter | PHA | Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2025-07-16T21:37:06-04:00 | |
| 3387159 | DESIMONE CONSULTING, LLC 20dc7daa-a070-4103-96f0-29a88672977e | Q2 | DESIMONE CONSULTING, LLC | 400931695 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2025 | second_quarter | PHA | Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to the EPIC (Ensuring Pathways to Innovative Cures) Act, H.R.1492/S.832. Most Favored Nation (MFN) policy activity related to the reconciliation process, H.R.1, One Big Beautiful Bill Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-16T23:11:12-04:00 | |
| 3387591 | BUCHANAN INGERSOLL & ROONEY PC b8d322fe-3f82-4b06-8c09-ceebc8311dd1 | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | AIM IMMUNOTECH INC. | 2025 | second_quarter | PHA | Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-17T10:04:30-04:00 | |
| 3387775 | TRUSYNERGY c455cbf5-a9a1-4e59-9122-26cf8c102299 | Q2 | TRUSYNERGY | 401107715 | BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) | 2025 | second_quarter | PHA | Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-07-17T10:52:19-04:00 | |
| 3387806 | CORNERSTONE GOVERNMENT AFFAIRS, INC. f4bc0ede-41f7-4a52-aeeb-342210bbc155 | Q2 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2025 | second_quarter | PHA | Health-related issues including reimbursement, research, public-health & clinical care. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2025-07-17T10:56:02-04:00 | |
| 3388035 | INDEPENDENT PHARMACY COOPERATIVE c5f7002f-150a-41c2-bcb6-e390fa50604f | Q2 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2025 | second_quarter | PHA | IPC supports Protecting Pharmacies in Medicaid Act (S.927) IPC supports Patients Before Middlemen Act (S 882). IPC supports Continuing Resolution (H.R. 1968) ECAPS provision CMS Implementation of drug provisions of the IRA 2022-including the drug negotiation provision with changes and prescription drug co-pay spread option. IPC supports the removal of the mandatory NADAC reporting requirement in the OBBB without an adequate and defined corresponding professional dispensing fee. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-17T11:37:25-04:00 | |
| 3388070 | FOLEY & LARDNER LLP f7c31200-579a-4ab5-924a-097ef023a396 | Q2 | FOLEY & LARDNER LLP | 15042 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2025 | second_quarter | PHA | Issues related to manufacturing and pharmaceutical trade. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2025-07-17T11:43:31-04:00 | |
| 3388078 | FOLEY & LARDNER LLP a8768724-2577-4ddc-97c8-34fef71132d0 | Q2 | FOLEY & LARDNER LLP | 15042 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2025 | second_quarter | PHA | Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2025-07-17T11:45:38-04:00 | |
| 3388332 | FOLEY & LARDNER LLP 045bb1a1-f5b1-4ef7-b059-7ffb265af98a | Q2 | FOLEY & LARDNER LLP | 15042 | FOUNDATION CONSUMER HEALTHCARE LLC | 2025 | second_quarter | PHA | Regulations affecting non-prescription drugs | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 120000 | 0 | 0 | 2025-07-17T12:21:27-04:00 | |
| 3388735 | COREWELL HEALTH 4bc02af9-49bc-4e04-9658-15bbf3ebc93d | Q2 | COREWELL HEALTH | 298455 | COREWELL HEALTH | 2025 | second_quarter | PHA | 340B - Reforms to protect the integrity of the program. PBM Reform/Oversight. Transparency and high costs associated with prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 270000 | 0 | 0 | 2025-07-17T13:41:44-04:00 | |
| 3388754 | ELI LILLY AND COMPANY 7efc13b2-dca2-4676-975a-bfeb0075f1b2 | Q2 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2025 | second_quarter | PHA | Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act | HOUSE OF REPRESENTATIVES,SENATE | 2700000 | 0 | 0 | 2025-07-17T13:44:51-04:00 | |
| 3388833 | MASSACHUSETTS MEDICAL SOCIETY 79d611f3-05a8-418b-8fde-33cee4d53d9c | Q2 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2025 | second_quarter | PHA | Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-17T14:05:27-04:00 | |
| 3389021 | BRAVO GROUP d078306d-c7de-4948-85a2-926c90992f14 | Q2 | BRAVO GROUP | 296293 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | second_quarter | PHA | Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-17T14:29:53-04:00 | |
| 3389249 | FAEGRE DRINKER BIDDLE & REATH LLP 1e6fe2fb-a020-4d19-8ff6-117f2635b370 | Q2 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) | 2025 | second_quarter | PHA | Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; Social media and online marketplace platform accountability; SHOP SAFE Act; Cooper Davis Act; Protecting Patients from Deceptive Drug Ads Act (S. 652). | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-17T14:57:25-04:00 | |
| 3389288 | FAEGRE DRINKER BIDDLE & REATH LLP 56134639-87dd-4fb6-b500-b79c27bc5e0a | Q2 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | NATIONAL ASSOCIATION OF BOARDS OF PHARMACY | 2025 | second_quarter | PHA | Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-17T15:01:37-04:00 | |
| 3389435 | BLUECROSS BLUESHIELD OF TENNESSEE 28f2fd1c-540d-4fe9-8503-920e41a8cd08 | Q2 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2025 | second_quarter | PHA | Pharmacy Benefit Managers; Prescription Drug Cost; Delinking of Pharmacy H.R. 3839 - To amend the Federal Food, Drug, and Cosmetic Act to provide for increased transparency in generic drug applications S. 150- Affordable Prescriptions for Patients Act To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. | HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2025-07-17T15:17:15-04:00 | |
| 3389518 | THE KPM GROUP DC LLC e8f3e911-5047-4294-ab3c-5dafe7403582 | Q2 | THE KPM GROUP DC LLC | 401105372 | REZOLUTE | 2025 | second_quarter | PHA | S.4426, Promising Pathway Act 2.0 (118th Congress) | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-17T15:28:10-04:00 | |
| 3389526 | THE KPM GROUP DC LLC 0e577820-0466-47d7-a96a-015e776d4579 | Q2 | THE KPM GROUP DC LLC | 401105372 | PRAXIS PRECISION MEDICINES | 2025 | second_quarter | PHA | H.R.1262/S.932, Give Kids a Chance Act H.R.1509/S.752, Accelerating Kids Access to Care Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-17T15:29:15-04:00 | |
| 3389548 | THE KPM GROUP DC LLC 7f4f7ec9-3acc-4ae2-9490-c3f7c30fe625 | Q2 | THE KPM GROUP DC LLC | 401105372 | INOZYME PHARMA | 2025 | second_quarter | PHA | H.R.1262/S.932 - Give Kids a Chance Act H.R.946 - ORPHAN Cures Act H.R. 1414 - Cameron's Law H.R.1532/S.822 - Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1492 - Ensuring Pathways to Innovative Cures (EPIC) Act | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-17T15:32:33-04:00 | |
| 3389559 | THE KPM GROUP DC LLC d24a7e52-d854-4791-a7ea-67c3951466fa | Q2 | THE KPM GROUP DC LLC | 401105372 | THE HS COALITION | 2025 | second_quarter | PHA | S.864, Help Ensure Lower Patient (HELP) Copays Act H. Res 484, Expressing support for the recognition of "Hidradenitis Suppurativa Awareness Week" | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2025-07-17T15:33:53-04:00 | |
| 3389567 | THE KPM GROUP DC LLC 0432e7a3-c6f5-4aa0-8ab2-943f56a1f327 | Q2 | THE KPM GROUP DC LLC | 401105372 | ASTRIA THERAPEUTICS, INC. | 2025 | second_quarter | PHA | S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-17T15:34:44-04:00 | |
| 3389613 | THORN RUN PARTNERS e0b8393c-c2d2-49ec-b445-d12a4ea9bd25 | Q2 | THORN RUN PARTNERS | 400534596 | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2025 | second_quarter | PHA | Pharmaceutical reimbursement issues. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-17T15:36:24-04:00 | |
| 3389759 | BRIDGEBIO PHARMA, INC. 45fc083f-9cfa-435e-89ff-f8e47b474e71 | Q2 | BRIDGEBIO PHARMA, INC. | 401107898 | BRIDGEBIO PHARMA, INC. | 2025 | second_quarter | PHA | Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction, Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822 | HOUSE OF REPRESENTATIVES,SENATE | 320000 | 0 | 0 | 2025-07-17T15:55:36-04:00 | |
| 3389812 | HOLLAND & KNIGHT LLP 238f992f-2424-4c23-8752-e60f838fe324 | Q2 | HOLLAND & KNIGHT LLP | 18466 | VIATRIS INC | 2025 | second_quarter | PHA | S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-17T16:05:12-04:00 | |
| 3389839 | BALLARD PARTNERS a4dbbdc0-7421-4c27-a1a4-3d712f2047d0 | Q2 | BALLARD PARTNERS | 401104288 | RIO BIOPHARMACEUTICALS, INC. | 2025 | second_quarter | PHA | Assisting with applications before the Food & Drug Administration for generic pharmaceutical approvals. | Health & Human Services, Dept of (HHS) | 100000 | 0 | 0 | 2025-07-17T16:08:55-04:00 | |
| 3389948 | BALLARD PARTNERS 56abb056-01cc-4191-91e5-b2a3a81d69e5 | Q2 | BALLARD PARTNERS | 401104288 | THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) | 2025 | second_quarter | PHA | 340B Drug Discount Program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2025-07-17T16:23:49-04:00 | |
| 3390137 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 16fbbcca-9563-4ae9-8179-3714f2ac8370 | Q2 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2025 | second_quarter | PHA | - The Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act - Fluoride and fluoridated water - Additive Ingredients in Drug Products - Over-the-Counter Tests - Pediatric Labeling | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 196425 | 0 | 0 | 2025-07-17T16:53:04-04:00 | |
| 3390268 | FAMILIES USA FOUNDATION, INC. 83435346-38e0-49fa-ae06-3f147a42849e | Q2 | FAMILIES USA FOUNDATION, INC. | 14108 | FAMILIES USA FOUNDATION INC | 2025 | second_quarter | PHA | S.832/H.R.1492Ensuring Pathways to Innovative Cures ActToamend title XI of the Social Security Acttoequalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R.946Orphan Cures ActTo amend title XI of the Social Security Act to expand and clarify the exclusion fororphandrugs under the Drug Price Negotiation Program. | HOUSE OF REPRESENTATIVES,SENATE | 18000 | 0 | 0 | 2025-07-17T17:17:29-04:00 | |
| 3390405 | BROYDRICK & ASSOCIATES 78dc81a1-9f45-4a83-8920-81752728341d | Q2 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2025 | second_quarter | PHA | Funding new drug for PTSD and COVID 19, BARDA appropriations. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-17T17:55:29-04:00 | |
| 3390507 | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) 5f236f4e-3803-4be7-b32b-ad8ccf0e7edf | Q2 | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | 24566 | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | 2025 | second_quarter | PHA | H.R. 3164, Ensuring Community Access to Pharmacist Services Act | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 460000 | 0 | 0 | 2025-07-17T18:22:11-04:00 | |
| 3390563 | TAUZIN CONSULTANTS, LLC 1fb6be3f-66c5-4f08-a184-1668c6186f53 | Q2 | TAUZIN CONSULTANTS, LLC | 400671007 | RAZORMETRICS | 2025 | second_quarter | PHA | Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-17T18:40:24-04:00 | |
| 3390656 | POLARIS GOVERNMENT RELATIONS, LLC c9b48435-0f6e-4fc9-a7b7-fda2aa6f6a86 | Q2 | POLARIS GOVERNMENT RELATIONS, LLC | 307730 | CIGNA CORPORATION | 2025 | second_quarter | PHA | Drug pricing and issues facing the pharmacy benefit manager industry generally | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2025-07-17T19:14:17-04:00 | |
| 3390671 | TRAVERE THERAPEUTICS d2c90ac0-b200-42cb-b14b-7376689fed21 | Q2 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2025 | second_quarter | PHA | HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals | HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2025-07-17T19:20:32-04:00 | |
| 3390706 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 6810b0f3-f68a-4993-8423-a43ae5495c5b | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | WALGREEN CO. | 2025 | second_quarter | PHA | Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare Issues regarding immunization and vaccines | SENATE | 50000 | 0 | 0 | 2025-07-17T19:27:57-04:00 | |
| 3390985 | AEGIS LLC afbfccc5-1bb3-4398-b9c3-97173a188c49 | Q2 | AEGIS LLC | 401108688 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | second_quarter | PHA | Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-18T06:49:24-04:00 | |
| 3390987 | AEGIS LLC a46fd06e-25b1-4946-9e59-e4eeebae55a7 | Q2 | AEGIS LLC | 401108688 | TRIS PHARMA, INC. | 2025 | second_quarter | PHA | ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission. | HOUSE OF REPRESENTATIVES,Natl Highway Traffic Safety Administration (NHTSA),SENATE | 50000 | 0 | 0 | 2025-07-18T06:52:59-04:00 | |
| 3391325 | VAN SCOYOC ASSOCIATES 584032ed-6297-4552-961c-c190aad653d0 | Q2 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2025 | second_quarter | PHA | Temperature monitoring technology issues, as follows: H.R.3838, Streamlining Procurement for Effective Execution and Delivery Act of 2025, National Defense Authorization FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2026 | SENATE | 30000 | 0 | 0 | 2025-07-18T08:54:06-04:00 | |
| 3391792 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 09740c7f-34e3-4e24-854a-9c6b22dbdb6a | Q2 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2025 | second_quarter | PHA | Increasing the affordability and accessibility of treatments for Parkinsons disease. | HOUSE OF REPRESENTATIVES,SENATE | 170000 | 0 | 0 | 2025-07-18T09:57:26-04:00 | |
| 3391836 | DLA PIPER LLP (US) 444f7fea-eeff-45b0-811d-17fcedd3d592 | Q2 | DLA PIPER LLP (US) | 76855 | NOVARTIS | 2025 | second_quarter | PHA | Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-07-18T10:00:45-04:00 | |
| 3392964 | DA VINCI GROUP 13eb35dd-f937-4fbe-8e9d-13791b08a0cb | Q2 | DA VINCI GROUP | 11548 | PROCARE, INC. | 2025 | second_quarter | PHA | Issues related to PBM reform. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-18T11:20:14-04:00 | |
| 3393012 | VAN SCOYOC ASSOCIATES 8ee29d27-d477-4590-9124-a667d7c5491a | Q2 | VAN SCOYOC ASSOCIATES | 39837 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2025 | second_quarter | PHA | H.R.3164, Ensuring Community Access to Pharmacist Services Act, Entirety S.891, Bipartisan Health Care Act, PBM reform related issues H.R.2484, Seniors' Access to Critical Medications Act of 2025, Entirety PBM Reform related issues H.R.1, One Big Beautiful Bill Act, PBM Reform | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-07-18T11:24:08-04:00 | |
| 3393054 | UC HEALTH 440848bc-2c5c-425f-b361-da992df0caab | Q2 | UC HEALTH | 401103195 | UC HEALTH | 2025 | second_quarter | PHA | 340B | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-18T11:27:42-04:00 | |
| 3393370 | BLUE CROSS BLUE SHIELD OF MICHIGAN aeb69928-d147-4684-a722-123353b43803 | Q2 | BLUE CROSS BLUE SHIELD OF MICHIGAN | 46676 | BLUE CROSS BLUE SHIELD OF MICHIGAN | 2025 | second_quarter | PHA | Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] H.R.5429 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and th… | HOUSE OF REPRESENTATIVES,SENATE | 265983 | 0 | 0 | 2025-07-18T11:46:45-04:00 | |
| 3393403 | W STRATEGIES, LLC 9962a390-e20d-4044-a965-641295c39e57 | Q2 | W STRATEGIES, LLC | 400605842 | PHLOW CORP. | 2025 | second_quarter | PHA | Education about efforts to provide greater resiliency in the drug supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-07-18T11:48:22-04:00 | |
| 3393504 | S-3 GROUP 74efcfd6-5ae9-4641-a63b-4ec002e1750d | Q2 | S-3 GROUP | 400774330 | GOODRX | 2025 | second_quarter | PHA | Issues regarding lower prescription drug prices for patients | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-07-18T11:54:31-04:00 | |
| 3393674 | VENN STRATEGIES 91fbde99-daf1-458c-933b-080988ea60f8 | Q2 | VENN STRATEGIES | 65191 | THE PERSONAL CARE PRODUCTS COUNCIL | 2025 | second_quarter | PHA | Issues related to personal care products, including the Supporting Accessible, Flexible, and Effective (SAFE) Sunscreen Standards Act, Humane Cosmetics Act, and OMUFA. | HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 40000 | 0 | 0 | 2025-07-18T12:09:21-04:00 | |
| 3393678 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 64e1fde9-2631-4a79-8a60-defcb93e57a8 | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | LILLY USA, LLC | 2025 | second_quarter | PHA | Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act | SENATE | 90000 | 0 | 0 | 2025-07-18T12:09:37-04:00 | |
| 3393918 | ICE MILLER LLP 0e715340-652a-4f67-bd4d-102bb7a357db | Q2 | ICE MILLER LLP | 67854 | COALITION FOR RESPONSIBLE COMPOUDING INC. | 2025 | second_quarter | PHA | Educating Congress and the Executive Branch about compounding procedures and standards. | Food & Drug Administration (FDA) | 0 | 0 | 2025-07-18T12:28:05-04:00 | ||
| 3393927 | KAISER FOUNDATION HEALTH PLAN INC. 34fb9c7c-22ee-4e0e-a8ce-6798e145ffa8 | Q2 | KAISER FOUNDATION HEALTH PLAN INC. | 21027 | KAISER FOUNDATION HEALTH PLAN INC | 2025 | second_quarter | PHA | Legislation and regulation regarding pharmaceutical pricing, coverage and care; retail and inpatient pharmacy operations and the role of pharmacy benefit managers. S.527 - Prescription Pricing for the People Act S.1040 - Drug Competition Enhancement Act S.1041 - Affordable Prescriptions for Patients Act S.1097 - Interagency Patent Coordination and Improvement Act S.1095 - Stop STALLING Act S.1096 - Preserve Access to Affordable Generics and Biosimilars Act S.1553 - PREVAIL Act S.1546 - Patent Eligibility Restoration Act of 2025 | HOUSE OF REPRESENTATIVES,SENATE | 480000 | 0 | 0 | 2025-07-18T12:28:26-04:00 | |
| 3394065 | BCBSM, INC. f2a00e98-e03a-4d70-97ba-90146f3c3072 | Q2 | BCBSM, INC. | 5687 | BCBSM INC | 2025 | second_quarter | PHA | Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: S… | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-07-18T12:45:56-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);